Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-58P is a pseudogene annotated as "RNA, U4 small nuclear 58, pseudogene." It is named and classified similarly to genes encoding U4 small nuclear RNAs, but as a pseudogene, it is not functionally transcribed into a functional product, nor does it appear to play a direct biological or pathological role. Unlike its functional counterparts such as RNU4-2, which encodes an essential U4 snRNA involved in the spliceosome and associated with neurodevelopmental disorders such as ReNU syndrome[1][3][4][5][7], RNU4-58P does not encode a functional RNA and has not been implicated in any diseases, drug interactions, or clinical functions. Its presence in the genome reflects evolutionary duplication or retrotransposition rather than an active molecular role.\n\nKey distinction: RNU4-2 and related active snRNA genes are important spliceosomal components with established disease relevance, while RNU4-58P is a non-functional pseudogene and not considered a therapeutic target[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 58, pseudogene (RNU4-58P).